Pegvisomant

What it's for

Pegvisomant is a PEGylated genetically engineered growth hormone analog that antagonizes the growth hormone receptors (lock-and-key landing spots on cells). It treats acromegaly by lowering IGF-1 when surgery/radiation/other meds are insufficient.

What it does for the body

It treats acromegaly by lowering IGF-1 when surgery/radiation/other meds are insufficient. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

It binds growth hormone receptors (lock-and-key landing spots on cells) without proper receptors (lock-and-key landing spots on cells) dimer signaling, blocking endogenous growth hormone action and reducing IGF-1. Imagine a thermostat for growth-hormone release: some peptides nudge the brain's release signals up, rather than pouring hormone in directly.

Research context

Bottom line for readers: Pegvisomant has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Hormones research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Pegvisomant — FDA.gov search
• ClinicalTrials.gov search: Pegvisomant — U.S. clinical trials registry
• Drugs@FDA search: Pegvisomant — FDA drug database (if approved)
• PubMed search: Pegvisomant — NCBI PubMed
• PubMed Central search: Pegvisomant — NCBI PMC

Reference

No ref on file.